Renal cell carcinoma
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DIS-RCC |
|---|---|
| Type | Disease |
| Aliases | HypernephromaRCCНирково-клітинна карцинома |
| Status | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-RCC-2024 SRC-NCCN-KIDNEY-2025 |
Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.
| icd_o_3_morphology | 8312/3 |
|---|---|
| icd_o_3_topography | ["C64.9"] |
| icd_10 | C64 |
| who_classification | Renal cell carcinoma — clear-cell / papillary / chromophobe (WHO 5th 2022) |
Notes
biomarker_driven — histology + IMDC risk drive selection. Adjuvant pembrolizumab approved per KEYNOTE-564.
Used By
Actionability
BMA-BAP1-MUT-RCC-PROGNOSTIC- BMA-BAP1-MUT-RCC-PROGNOSTICBMA-MET-AMP-RCC-PAPILLARY- MET-driven papillary type-1 RCC: cabozantinib superior to sunitinib in MET-driven pRCC (P...BMA-PIK3CA-HOTSPOT-RCC- PIK3CA mutations rare in RCC; mTORi (everolimus, temsirolimus) approved 2L+ regardless of...BMA-TP53-MUT-RCC- TP53 mutation in RCC — common, adverse prognostic; not directly targeted. Per usual algor...BMA-TSC1-GERMLINE-TUBEROUS-SCLEROSIS- TSC1 germline pathogenic variants drive Tuberous Sclerosis Complex (TSC) — an mTOR-pathwa...BMA-TSC1-TSC-RENAL-AML- Everolimus (mTOR inhibitor) is FDA-approved (2012) for renal angiomyolipoma (AML) associa...BMA-TSC2-GERMLINE-TUBEROUS-SCLEROSIS- TSC2 germline pathogenic variants drive Tuberous Sclerosis Complex (TSC) — the more clini...
Algorithms
ALGO-COWDEN-CARRIER-SURVEILLANCE- ALGO-COWDEN-CARRIER-SURVEILLANCEALGO-HEREDITARY-MELANOMA-SURVEILLANCE- ALGO-HEREDITARY-MELANOMA-SURVEILLANCEALGO-RCC-METASTATIC-1L- ALGO-RCC-METASTATIC-1LALGO-RCC-METASTATIC-2L- ALGO-RCC-METASTATIC-2LALGO-VHL-CARRIER-SURVEILLANCE-VHL-ALLIANCE- ALGO-VHL-CARRIER-SURVEILLANCE-VHL-ALLIANCE
Disease
DIS-LEIOMYOSARCOMA- Leiomyosarcoma (LMS)DIS-PARAGANGLIOMA- Paraganglioma (PGL)DIS-PHEOCHROMOCYTOMA- Pheochromocytoma and paraganglioma (PPGL)DIS-WILMS- Wilms tumor (nephroblastoma)
Indication
IND-BAP1-SUSPICION-PREVENTION-ENHANCED-SURVEILLANCE- IND-BAP1-SUSPICION-PREVENTION-ENHANCED-SURVEILLANCEIND-BAP1-SUSPICION-PREVENTION-GENETIC-COUNSELING- IND-BAP1-SUSPICION-PREVENTION-GENETIC-COUNSELINGIND-BHD-FLCN-CARRIER-OBSERVATION- IND-BHD-FLCN-CARRIER-OBSERVATIONIND-BHD-FLCN-CARRIER-SURVEILLANCE- IND-BHD-FLCN-CARRIER-SURVEILLANCEIND-CASCADE-VHL-FDR-POSITIVE-SURVEILLANCE- IND-CASCADE-VHL-FDR-POSITIVE-SURVEILLANCEIND-CASCADE-VHL-FDR-POSITIVE-TESTING- IND-CASCADE-VHL-FDR-POSITIVE-TESTINGIND-HLRCC-CARRIER-INTENSIFIED- IND-HLRCC-CARRIER-INTENSIFIEDIND-HLRCC-CARRIER-SURVEILLANCE- IND-HLRCC-CARRIER-SURVEILLANCEIND-HLRCC-SUSPICION-PREVENTION-ENHANCED-SURVEILLANCE- IND-HLRCC-SUSPICION-PREVENTION-ENHANCED-SURVEILLANCEIND-HLRCC-SUSPICION-PREVENTION-GENETIC-COUNSELING- IND-HLRCC-SUSPICION-PREVENTION-GENETIC-COUNSELINGIND-HPRC-CARRIER-INTENSIFIED- IND-HPRC-CARRIER-INTENSIFIEDIND-HPRC-CARRIER-SURVEILLANCE- IND-HPRC-CARRIER-SURVEILLANCEIND-HPRC-SUSPICION-PREVENTION-ENHANCED-SURVEILLANCE- IND-HPRC-SUSPICION-PREVENTION-ENHANCED-SURVEILLANCEIND-HPRC-SUSPICION-PREVENTION-GENETIC-COUNSELING- IND-HPRC-SUSPICION-PREVENTION-GENETIC-COUNSELINGIND-RCC-ADJUVANT-PEMBRO- IND-RCC-ADJUVANT-PEMBROIND-RCC-METASTATIC-1L-LENV-PEMBRO- IND-RCC-METASTATIC-1L-LENV-PEMBROIND-RCC-METASTATIC-1L-NIVO-CABO- IND-RCC-METASTATIC-1L-NIVO-CABOIND-RCC-METASTATIC-1L-NIVO-IPI- IND-RCC-METASTATIC-1L-NIVO-IPIIND-RCC-METASTATIC-1L-PEMBRO-AXI- IND-RCC-METASTATIC-1L-PEMBRO-AXIIND-RCC-METASTATIC-2L-BELZUTIFAN- IND-RCC-METASTATIC-2L-BELZUTIFANIND-RCC-METASTATIC-2L-CABOZANTINIB- IND-RCC-METASTATIC-2L-CABOZANTINIBIND-RCC-NON-CLEAR-CELL-1L-CABOZANTINIB- IND-RCC-NON-CLEAR-CELL-1L-CABOZANTINIBIND-RCC-VHL-DISEASE-BELZUTIFAN- IND-RCC-VHL-DISEASE-BELZUTIFANIND-TSC-CARRIER-INTENSIFIED- IND-TSC-CARRIER-INTENSIFIEDIND-TSC-CARRIER-SURVEILLANCE- IND-TSC-CARRIER-SURVEILLANCEIND-VHL-SUSPICION-PREVENTION-ENHANCED-SURVEILLANCE- IND-VHL-SUSPICION-PREVENTION-ENHANCED-SURVEILLANCEIND-VHL-SUSPICION-PREVENTION-GENETIC-COUNSELING- IND-VHL-SUSPICION-PREVENTION-GENETIC-COUNSELING
Procedures
PROC-NEPHRON-SPARING-PARTIAL-NEPHRECTOMY-VHL- Nephron-sparing partial nephrectomy for VHL renal lesion (≥3 cm threshold)
Questionnaires
QUEST-RCC-1L-STUB- Renal cell carcinoma — first line
Red flag
RF-ACTIVE-AUTOIMMUNE-DISEASE-ICI-RISK- Patient with active or incompletely controlled pre-existing autoimmune or inflammatory di...RF-BAP1-CONFIRMED-CARRIER- Confirmed germline pathogenic / likely-pathogenic variant in the BAP1 gene — BAP1 tumor p...RF-BAP1-FAMILY-HISTORY-SUSPICION- Family pedigree suggestive of BAP1 tumor predisposition syndrome — confirmed germline BAP...RF-BHD-FLCN-CONFIRMED-CARRIER- Confirmed germline pathogenic / likely-pathogenic variant in FLCN (folliculin) — Birt-Hog...RF-CASCADE-VHL-FDR-POSITIVE- A first-degree relative of the patient (parent, sibling, or child) has a documented posit...RF-COWDEN-CONFIRMED-CARRIER- Confirmed germline pathogenic / likely-pathogenic variant in the PTEN gene (Cowden syndro...RF-COWDEN-FAMILY-HISTORY-SUSPICION- Family pedigree suggestive of Cowden syndrome / PTEN hamartoma tumor syndrome (PHTS): any...RF-HLRCC-CONFIRMED-CARRIER- Patient has a confirmed germline FH (fumarate hydratase) pathogenic variant (Hereditary L...RF-HLRCC-FAMILY-HISTORY-SUSPICION- Family pedigree suggestive of Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) syn...RF-HPRC-CONFIRMED-CARRIER- Confirmed germline pathogenic / likely-pathogenic variant in the MET proto-oncogene — Her...RF-HPRC-FAMILY-HISTORY-SUSPICION- Family pedigree suggestive of HPRC (Hereditary Papillary Renal Cancer) — MET-driven type...RF-LIFESTYLE-OBESITY-CANCER-PREVENTION- Obesity — BMI ≥30 kg/m² (per WHO definition) — OR class 2/3 obesity with BMI ≥35 / ≥40. I...RF-RCC-FRAILTY-AGE- Age ≥80 + ECOG ≥2 + comorbidity — ICI doublet toxicity prohibitive.RF-RCC-FRAILTY-ECOG2- Frailty or ECOG 2 status that may favor a less intensive RCC treatment approach.RF-RCC-HIGH-RISK-BIOLOGY- Sarcomatoid features OR rapid TKI progression — predicts ICI-doublet benefit; non-clear-c...RF-RCC-IMDC-INTERMEDIATE-POOR-RISK- IMDC (International Metastatic RCC Database Consortium) intermediate or poor risk score i...RF-RCC-INFECTION-SCREENING- Active or latent infection requiring resolution / prophylaxis before initiating ICI doubl...RF-RCC-ORGAN-DYSFUNCTION- Solitary kidney OR baseline CrCl <50 mL/min — limits cisplatin alternatives + impacts sur...RF-RCC-TRANSFORMATION-PROGRESSION- CNS metastases — ICI doublet retains intracranial activity; cabozantinib + nivolumab also...RF-SDH-CONFIRMED-CARRIER- Confirmed germline pathogenic / likely-pathogenic variant in one of the SDHx genes — SDHB...RF-SDH-FAMILY-HISTORY-SUSPICION- Family pedigree suggestive of SDH (succinate dehydrogenase) deficiency syndrome — confirm...RF-TSC-CONFIRMED-CARRIER- Confirmed germline pathogenic / likely-pathogenic variant in TSC1 (hamartin) or TSC2 (tub...RF-VHL-CONFIRMED-CARRIER- Patient has a confirmed germline VHL pathogenic variant (positive germline test result, d...RF-VHL-FAMILY-HISTORY-SUSPICION- Family pedigree suggestive of Von Hippel-Lindau (VHL) disease: any of (a) a family member...
Sources
SRC-CHECKMATE-214-MOTZER-2018- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell CarcinomaSRC-CHECKMATE-9ER-CHOUEIRI-2021- Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell CarcinomaSRC-CLEAR-MOTZER-2021- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell CarcinomaSRC-COMPARZ-MOTZER-2013- Pazopanib versus sunitinib in metastatic renal-cell carcinomaSRC-ESMO-RCC-2024- ESMO Renal Cell CarcinomaSRC-KEYNOTE-426-RINI-2019- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell CarcinomaSRC-KEYNOTE-564-CHOUEIRI-2021- Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell CarcinomaSRC-METEOR-CHOUEIRI-2016- Cabozantinib versus Everolimus in Advanced Renal-Cell CarcinomaSRC-NCCN-KIDNEY-2025- NCCN Kidney CancerSRC-VEG105192-STERNBERG-2010- Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized...